



INVESTOR PRESENTATION

MARCH 2021

DISCLAIMER

This presentation has been prepared by Osteopore Limited and its related entities (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US Disclosure

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

TRANSFORMATIVE BONE REGENERATION PRODUCTS



BREAKTHROUGH TECHNOLOGY

Unique 3D printed implants that facilitate vascularisation to accelerate bone and tissue regeneration



IMPROVES LIVES

Extremely low probability of issues after surgery compared to bone grafts and permanent implants



REVENUE INCREASING

Revenue is growing as surgeons increasingly switch from traditional products to Osteopore implants

TARGETING THE SIGNIFICANTLY UNTAPPED US\$3.9BN BONE GRAFT & US\$100BN PERMANENT IMPLANT MARKET WITH SUPERIOR PRODUCTS


INVESTMENT HIGHLIGHTS

REGULATORY CLEARANCE

Osteopore's products are cleared by the US FDA, Australian TGA and some bear the CE mark of conformity

SCALABLE BUSINESS MODEL

High margin products with low manufacturing capital intensity provide significant opportunity to scale the business and enter new markets



GROWING REVENUE

AUD\$1.5 million in revenue for the twelve month period to 31 December 2020, with around 50,000 successful treatments to date

HIGHLY CREDENTIALLED TEAM

The Company has a highly credentialed, collaborative and experienced team to progress the commercialisation and expansion of the Company's technology

ROBUST CASH POSITION TO DRIVE GROWTH

Shares on Issue ^A 117.2m

Total Options on Issue ^B 13.1m

Market Cap @ \$0.44c ^C \$51.5m

EV @ \$0.44 ^C \$42.5m

CASH BALANCE ^D \$9.0m



FY20 Average Quarterly Net Operating Cash Used (\$388k)

A: Shares on Issue includes 16.0m placement shares in August 2020.

B: 9.7m options with an exercise price of \$0.25 and an expiry date of 30 June 2022, 0.4m options with an exercise price of \$1.00 and an expiry date in December 2022, 3m options with exercise price of \$1.20 and expiry August 2023. Option incentives held by executive management, directors & advisors.

C: Market Close, 1 March 2021

D: Cash balance at 31 December 2020



HIGHLY CREDENTIALIALED TEAM



**GOH
KHOON
SENG**
CEO

30-year career spanning both start-ups and global multinational corporations

The last 20 years were at Medtronic Inc Inc and Edwards Lifesciences Asia



**TEOH
SWEE
HIN**
Non-Exec Director

Co-founder of Osteopore

Prof. Teoh has deep research experience in load bearing scaffolds for tissue regeneration and remodeling



**BRETT
SANDERCOCK**
Non-Exec Chairman

Current CFO of Resmed (ASX:RMD / NYSE: RMD)

Senior executive at Norton Abrasives (Saint-Gobain)



**GEOFF
POCOCK**
Non-Exec Director

20 years corporate finance and technology commercialisation experience

Formerly Managing Director of Hazer Group Ltd (ASX:HZR) and Non-Executive Director of ASX listed and private companies



**STUART
CARMICHAEL**
Non-Exec Director

Partner of Ventnor Capital

Non-Executive Chairman and Director of various ASX listed entities



**CARL
RUNDE**
Chief Financial Officer

Former Vice President Corporate Systems and FP&A at ResMed (NYSE:RMD / ASX:RMD)

Over 20 years of international experience as a finance business partner in commercial, R&D, and manufacturing functions in the medical device industry

BREAKTHROUGH BIORESORBABLE PRODUCTS FOR MULTIPLE APPLICATIONS



Osteoplug™

Implant that is used for covering Burr Holes (holes in skull) after neurosurgery

REGULATORY APPROVAL

SALES GENERATING



Osteomesh™

Implant used in craniofacial surgery to repair bone in the skull, neck and jaw, including repairing orbital floor fractures

REGULATORY APPROVAL



SALES GENERATING



OSTEOPORE PSI

Custom-designed patient specific implants used throughout the body

SALES GENERATING




Osteostrip

Implant that is used to fill the void following a craniotomy (the surgical removal of part of the bone from the skull to expose the brain)

REGULATORY APPROVAL

SALES GENERATING




DENTAL

Dental plug which promotes vertical bone growth in the jaw following tooth removal

REGULATORY APPROVAL *

SALES GENERATING



ORTHOPAEDIC

A scaffold used in a range of orthopaedic procedures, where significant lengths of long bones have been damaged

INVESTIGATIVE DEVICE

SPECIAL ACCESS SALES

HOW OUR IMPLANTS FACILITATE BONE GROWTH


1



BURR HOLE IS DRILLED

Patients needing surgical repair for skull fractures usually receive a “burr hole” during surgery, which is drilled into the skull to relieve pressure often resulting from hemorrhage


2



IMPLANT DRAWS IN BLOOD

Osteopore’s proprietary 3D printed polymer scaffold is made up of biomimetic microstructures that allow blood to be drawn into the implant before inserting


3



BONE GROWS ON SCAFFOLDS

Once in the skull the scaffold attracts cells and blood vessels, facilitating bone growth in-between the microstructures

4



IMPLANT DISSOLVES

The implants naturally and predictably dissolve over a period of 18-24 months to leave only natural healthy bone

SUPERIOR PRODUCTS FOR LARGE GLOBAL MARKETS

TRADITIONAL PROCEDURES



BONE GRAFT

A surgical procedure where bone material is harvested from the patient's own body and applied to the area to promote bone healing

- Potential for **infection** and lasting pain at harvest site
- Potential for body to **completely absorb the graft** with no bone regeneration

US\$3.9bn

Bone Graft Substitutes
Market by 2025



PERMANENT IMPLANTS

Used for a wide variety of different bone replacement / repair applications and are made from metal, ceramic and polymeric materials

- Non-biodegradable** with a high potential for post surgical complications
- Difficult to micro-adjust** for a better fit during the surgical procedure

US\$100bn

Permanent Implant Sales

Osteopore®



Highly customisable
to biomimic different
bone types



Proven to be
effective in ~50k
procedures



Naturally dissolves
over a predictable
time frame



Leaves only
healthy bone
tissue



Extremely low post
surgery complication
rates to date



Unlikely
inflammation
or infection



Implants can be easily modified
during surgery for a more custom fit

Osteopore implants **do not** require any major changes to current clinical procedures

IMPROVED PATIENT OUTCOMES & LOWER HEALTHCARE COSTS

- Osteopore products address an unmet clinical need by providing readily adaptable implants and reducing complication rates after surgery
- Provides hospitals, clinicians and patients with a proven solution that expedites recovery and lowers costs that may occur with traditional procedures in the event of complications

Bone Graft **6 – 19%** ^{1,2,3}

REPORTED COMPLICATION RATES

Permanent Implants **25 – 33%** ^{4,5,6}


REPORTED COMPLICATION RATES

Osteopore™ **0.01%**

SCALABLE & CUSTOMISABLE MANUFACTURING

All Osteopore products are fabricated in-house using proprietary 3D printing technology

- Rapid design, manufacturing and delivery of implants to anywhere in the world
- Unique low cost manufacturing process
- Ability to print autonomously at scale
- Increase or decrease production depending on global demand for different surgeries
- Maintains IP advantage and keeps trade secrets within the company



- Expanded manufacturing space by 100% in 2020
- Increased the number of printers from 8 to 14 to meet growing demand
- Increased the depth and breadth of expertise at all organisational levels

COMMERCIAL STRATEGY THAT BUILDS VALUE

#1 ACCELERATE REVENUE GROWTH

Revenue growth from our current product range is the highest corporate and commercial priority and will remain the focus throughout the lifecycle of the company

Osteo**plug**[™]

Osteo**mesh**[™]

Osteo**strip**

#2 DIVERSIFY PRODUCT RANGE

Osteopore is undertaking a number of development programs to launch new products and expand the scope of bone regeneration applications

#3 INNOVATE

Undertaking a number of early-stage, low-capital intensity development projects with large potential upside


COMPANY
VALUE

TIME FRAME

ACCELERATE REVENUE GROWTH

4X CONSECUTIVE QUARTERS OF REVENUE GROWTH

- Revenue providing a solid commercial foundation to build from, with the strategy in place to scale
- Achieving sales growth (41% cc YOY) despite healthcare and hospitals being disrupted due to COVID-19




23 | DISTRIBUTION PARTNERS

13 | PARTNERS SECURED IN 2020

EXPANDING DISTRIBUTION NETWORK

CURRENTLY TARGETING
~1.1 million⁷ CRANIAL
PROCEDURES GLOBALLY



REVENUE GROWTH STRATEGY

Leverage distribution partnerships in the key markets to accelerate revenue growth


Ensure sales teams and surgeons are educated and supported to drive adoption and sales

Leverage early adopters in sales and marketing campaigns to achieve product sales momentum

Increase underlying revenue through a mix of geographic expansion and adjacent clinical applications

SCALABLE OPPORTUNITY


- Osteopore has superior off-the-shelf products products that can be manufactured at scale and is used in over 1.1m procedures globally
- Long shelf-life products that can be stocked in a hospitals inventory system



Osteostrip



Osteoplug™



FOUNDATIONAL MARKETS



ASIA


- Well established and experienced distribution partner network in South Korea, Vietnam, Singapore and Australia
- 2020 constant currency year-on-year revenue growth of 39%
- Expanded range of clinical applications, including aesthetic surgery
- Emerging dental application sales in Singapore
- Orthopaedic application clinical trials underway in Singapore, Vietnam and Malaysia



AUSTRALIA & NZ


- Hired dedicated Business Development person in Sydney Australia
- Signed Australian & NZ distribution agreement with LMT Surgical
- Education and training for LMT sales team
- Achieve initial sales
- Support clinical trial for dental application

PRIORITY MARKET EXPANSION




Europe + UK

- Signed German-Austrian Distribution Agreement with MTG Medizintechnik Göhl GmbH
- Initial stocking order for Osteopore products from MTG Medizintechnik Göhl GmbH
- Identify & engage with Key Opinion Leaders surgeons across broader Europe + UK
- Achieve initial stocking orders





USA

- Signed US Distribution Agreement with Bioplate
- First “stocking” order with Bioplate
- Education and training for Bioplate sales team
- Secure additional U.S. distribution partnerships to cover more states
- Initiate 510k regulatory approval for dental and orthopedic products



CHINA

- Signed Co-operation agreement with Boao Yiling Life Care Centre in China
- Establish a subsidiary in the Suzhou Industrial Park as the first step towards obtaining Chinese regulatory approval
- Prepare NMPA dossier for regulatory approval



JAPAN

- Identify and engage KOL surgeons interested in adopting Osteopore products
- Identify potential distribution partners with strong ties to hospitals specialising in craniofacial procedures
- Develop the necessary education and training materials
- Achieve initial stocking order




DIVERSIFYING PRODUCT RANGE

DENTAL

Osteopore has developed an enhanced bioresorbable 3D-printed dental plug which promotes bone growth in the jaw, reducing the likelihood of bone shrinkage after tooth extraction.

Currently, patients requiring dental implants have to wait 3-6 months for bone to grow in the tooth socket after extraction.


Osteopore aims to deliver a shorter, reliable and less painful treatment process as the plugs are placed immediately after extraction, eliminating the need for bone grafts.^{8,9}



LIMITED SALES IN SINGAPORE

PURSUING TGA & USFDA
510K CLEARANCE & CE MARK

US\$1BN PA
DENTAL BONE GRAFT
ALTERNATIVES MARKET




US\$2BN PA
Sales of orthopaedic alternatives

ORTHOPAEDIC


Osteopore has successfully conducted first in human trials using the Osteopore scaffold in a range of orthopaedic procedures, where significant lengths of long bones have been damaged or diseased.

The Osteopore scaffold has recently demonstrated significant clinical success in tibia regenerations in Australia and Germany.^{8, 10}






INNOVATE



REGENERATION OF OTHER TISSUE

Osteopore has successfully completed animal trials for knee cartilage regeneration, and the Osteopore scaffold may also potentially be used to assist with the regeneration of other tissue types



VETERINARY MARKETS

Osteopore has successfully completed multiple animal trials for a number of different surgical applications which could possibly translate into products for the veterinarian market




ACCELERATING BONE REGENERATION

Osteopore is investigating the viability of incorporating compounds to produce novel polycaprolactone polymer composites which could be used development additional products for adjacent therapeutic and surgical areas

INNOVATE

Osteopore is conducting several early-stage research initiatives with high quality institutions that could present significant commercial opportunities.

2021 COMMERCIAL PRIORITIES



ACCELERATE REVENUE GROWTH

Leverage cranial and maxillofacial products with regulatory approval in significant Markets:



Establish a presence in new markets with a high volume of relevant procedures:



DIVERSIFICATION

Leverage dental product regulatory approval in Singapore to drive sales in Asia

Initiate a dental clinical trial in Australia as the basis for TGA product approval

Initiate FDA approval for dental and orthopaedic products for sale in the USA

Initiate regulatory approval for rhinoplasty in Korea




INNOVATION

Experiment with promising novel compound combinations, including PCL-TCP and PCL-TCP-Mg, facilitating bone and cell growth to improve healing time and patient outcomes

Engage with Terumo BCT to explore the opportunities to combine Osteopore's resorbable biomimetic scaffolds with Terumo's autologous biologics

Continuously improve manufacturing efficiency using proven technological improvements in 3D printing to cost effectively scale production

APPENDIX




GLOBAL REGULATORY APPROVAL

Osteopore is working towards necessary regulatory approval to expand sales in additional target jurisdictions including;



Brazil



China




Colombia



Egypt



Israel



Japan



Jordan



UAE



UK

SOURCES

- 1 Dimitriou, R., Mataliotakis, G. I., Angoules, A. G., Kanakaris, N. K., & Giannoudis, P. V. (2011). Complications following autologous bone graft harvesting from the iliac crest and using the RIA: a systematic review. *Injury*, 42, S3-S15.
- 2 Younger, E. M., & Chapman, M. W. (1989). Morbidity at bone graft donor sites. *Journal of orthopaedic trauma*, 3(3), 192-195.
- 3 Arrington, E. D., Smith, W. J., Chambers, H. G., Bucknell, A. L., & Davino, N. A. (1996). Complications of iliac crest bone graft harvesting. *Clinical Orthopaedics and Related Research®*, 329, 300-309
- 4 Giese, H., Meyer, J., Unterberg, A., & Beynon, C. (2020). Long-term complications and implant survival rates after cranioplastic surgery: a single-center study of 392 patients. *Neurosurgical Review*, 1-9.
- 5 Wiggins, A., Austerberry, R., Morrison, D., Ho, K. M., & Honeybul, S. (2013). Cranioplasty with custom-made titanium plates—14 years experience. *Neurosurgery*, 72(2), 248-256.
- 6 Thien, A., King, N. K., Ang, B. T., Wang, E., & Ng, I. (2015). Comparison of polyetheretherketone and titanium cranioplasty after decompressive craniectomy. *World neurosurgery*, 83(2), 176-180.
- 7 cetas healthcare (2020). Market research conducted for Osteopore on the global cranial procedure market.
- 8 Sparks, D. S., Saifzadeh, S., Savi, F. M., Dlaska, C. E., Berner, A., Henkel, J., ... & Hutmacher, D. W. (2020). A preclinical large-animal model for the assessment of critical-size load-bearing bone defect reconstruction. *Nature protocols*, 15(3), 877-924.
- 9 Zhang, Z., & Teoh, S. H. (2014). Novel 3D polycaprolactone scaffold for ridge preservation – a pilot randomised controlled clinical trial. *Clinical Oral Implants Research*, 26, 271-277.
- 10 van Griensven, M., Biberthaler, P., & Rosado Balmayor, E. (2015). Clinical approaches to the healing of long bone defects. In Schantz, J-T. & Hutmacher, D.W. (2020), *Advanced Therapies in Regenerative Medicine*, Vol. 2, World Scientific, (pp. 217-231).



Osteopore™

Carl Runde

Chief Financial Officer

M +61 400 118 017

E: carl_runde@osteopore.com